HUTCHMED (China) Limited American Depositary Shares (HCM) is a publicly traded Healthcare sector company. As of May 21, 2026, HCM trades at $12.32 with a market cap of $2.05B and a P/E ratio of 0.00. HCM moved +0.00% today. Year to date, HCM is -10.92%; over the trailing twelve months it is -10.25%. Its 52-week range spans $11.51 to $21.50. Analyst consensus is buy with an average price target of $20.00. Rallies surfaces HCM's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
HUTCHMED to Present HMPL-A580 IC50 1–10 nM Preclinical Data and Phase Ib/II Surufatinib Combo Updates at AACR: HUTCHMED will present preclinical HMPL-A580 data at AACR 2026 showing PI3K/PIKK payload IC50 of 1–10 nM and dose-dependent anti-tumor activity in EGFR+ xenograft models at 1–10 mg/kg. It will also reveal updated Phase Ib/II surufatinib plus sintilimib/capecitabine results in small bowel adenocarcinoma and exploratory Phase II surufatinib–AG pancreatic cancer data.
| Metric | Value |
|---|---|
| Price | $12.32 |
| Market Cap | $2.05B |
| P/E Ratio | 0.00 |
| EPS | $0.00 |
| Dividend Yield | 0.00% |
| 52-Week High | $21.50 |
| 52-Week Low | $11.51 |
| Volume | 74 |
| Avg Volume | 0 |
| Revenue (TTM) | $0 |
| Net Income | $0 |
| Gross Margin | 0.00% |
1 analysts cover HCM: 0 strong buy, 1 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is buy. Average price target: $20.00.